- Home
- AVNS vs NMRA Comparison
AVNS vs NMRA Comparison
Compare AVNS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVNS | NMRA |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.5M | 554.0M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AVNS | NMRA |
|---|---|---|
| Price | $24.62 | $2.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | 5.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $0.63 |
| 52 Week High | $24.70 | $3.65 |
Technical Indicators
Market Signals| Indicator | AVNS | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 92.06 | 43.78 |
| Support Level | $10.94 | $1.79 |
| Resistance Level | N/A | $2.22 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 1.31 | 0.02 |
| Stochastic Oscillator | 99.51 | 84.52 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.